GlassScriptPhysician profile
Robert F Callery
NPI 1780073213
$713.27
in general payments reported to CMS, 2019-2025
9 companies · $43.55 in 2025
The $43.55 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $79.73 · 2023: $378 · 2024: $76.60 · 2025: $43.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.04 | 2021-2024 | |
| Novo Nordisk INC | $136.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $85.45 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $50.03 | 2021-2023 | Emgality, Jardiance, Mounjaro |
| Abbott Laboratories | $19.03 | 2023 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $16.14 | 2022 | |
| Glaxosmithkline, LLC. | $15.78 | 2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $15.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Callery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.